COMPASS Pathways Makes 20,000 Does of Psilocybin

COMPASS Pathways synthesizes 20,000 doses of psilocybin for use in clinical trials.

July 2018

COMPASS Pathways creates 20,000 doses of synthetic psilocybin for use in clinical trials. Their current research focus is on treating patients with treatment-resistant depression.